Entrada Therapeutics (TRDA) Leases (2022 - 2025)
Historic Leases for Entrada Therapeutics (TRDA) over the last 4 years, with Q3 2025 value amounting to $62.1 million.
- Entrada Therapeutics' Leases fell 1579.3% to $62.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $62.1 million, marking a year-over-year decrease of 1579.3%. This contributed to the annual value of $71.1 million for FY2024, which is 1272.55% down from last year.
- As of Q3 2025, Entrada Therapeutics' Leases stood at $62.1 million, which was down 1579.3% from $65.7 million recorded in Q2 2025.
- Entrada Therapeutics' 5-year Leases high stood at $88.3 million for Q2 2023, and its period low was $14.2 million during Q1 2023.
- In the last 4 years, Entrada Therapeutics' Leases had a median value of $68.4 million in 2025 and averaged $58.5 million.
- Its Leases has fluctuated over the past 5 years, first plummeted by 5464.04% in 2023, then skyrocketed by 45420.79% in 2024.
- Quarter analysis of 4 years shows Entrada Therapeutics' Leases stood at $25.3 million in 2022, then surged by 221.59% to $81.5 million in 2023, then fell by 12.73% to $71.1 million in 2024, then fell by 12.65% to $62.1 million in 2025.
- Its last three reported values are $62.1 million in Q3 2025, $65.7 million for Q2 2025, and $68.4 million during Q1 2025.